Article

Biopsy at low PSA levels may translate into better clinical outcomes

Chicago-A biopsy of men with PSA levels of 2.6 to 4.0 ng/mL may detectorgan-confined prostate cancer more often than a biopsy in men with a PSAlevel >4.0 ng/mL, according to a large study from Washington University,St. Louis, presented yesterday. This may result in better clinical outcomes,including a lower biochemical progression rate.

Related Videos
Chad Tang, MD: Considerations for SBRT in metastatic RCC
Ravi Munver, MD, answers a question during a Zoom video interview
Interpreting ART toxicity and tolerability for bladder cancer, with Vedang Murthy, MD
1 KOL is featured in this series.
Related Content
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
October 10th 2024

Talazoparib/enzalutamide significantly boosts OS in mCRPC

Benjamin P. Saylor Jason M. Broderick Conor Killmurray
"The TALAPRO-2 results provide much-needed hope to patients who remain in high unmet need for effective treatment options," said Neeraj Agarwal, MD, FASCO.
Key updates from the AUA/ASRM male infertility guideline amendment
September 23rd 2024

Key updates from the AUA/ASRM male infertility guideline amendment

Urology Times staff
In this episode, Robert E. Brannigan, MD, and Juan J. Andino, MD, MBA, discuss the recent amendment to the AUA/ASRM guideline on male infertility.
Bridget Koontz, MD: 18F-flotufolastat demonstrates high detection rate in low PSA setting
October 10th 2024

Bridget Koontz, MD: 18F-flotufolastat demonstrates high detection rate in low PSA setting

Urology Times staff
"We found that as soon as we got to the range of biochemical recurrence-defined PSA—0.2 ng/mL and up—the detection rate was very high," says Bridget Koontz, MD, FASTRO.
Speaking of Urology: Dr. Winter on the use of vaginal estrogen
July 24th 2024

Speaking of Urology: Dr. Winter on the use of vaginal estrogen

Urology Times staff
In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.
Andrea Necchi, MD, on promising SunRISe-4 data of TAR-200 in MIBC
October 9th 2024

Andrea Necchi, MD, on promising SunRISe-4 data of TAR-200 in MIBC

Hannah Clarke
"Overall, TAR-200 is being tested with the aim of changing the therapeutic paradigm of patients with an early bladder cancer diagnosis, including non–muscle-invasive disease and muscle-invasive disease," says Andrea Necchi, MD.
Phase 1 data show encouraging safety of 177Lu-rhPSMA-10.1 injection in mCRPC
October 9th 2024

Phase 1 data show encouraging safety of 177Lu-rhPSMA-10.1 injection in mCRPC

Hannah Clarke
"We remain on track for the opening of phase 2 in the next few months. We also expect to see the full phase 1 results presented at a scientific meeting in 2025," says David E. Gauden, DPhil.
© 2024 MJH Life Sciences

All rights reserved.